Ms. Carolyn Bonner reports

MEDICUS PHARMA LTD. ANNOUNCES APPOINTMENT OF ERICA MONACO AS CHIEF OPERATING OFFICER

Medicus Pharma Ltd. has appointed Erica Monaco as chief operating officer.

Ms. Monaco is an accomplished C-suite professional with a successful track record as a leader in the pharmaceutical industry. She has spent the last decade in the dermatology sector with an extensive record of building start-up operations, accelerating change and driving process improvement. Mostly recently, Ms. Monaco was the chief executive officer of Biofrontera Inc. In her role as the chief executive officer of Biofrontera, where she joined as employee No. 2, Ms. Monaco grew a precommercial organization from FDA (Food and Drug Administration) approval through market introduction and commercial launch, posting a revenue growth at a CAGR (compound annual growth rate) over 80 per cent and completing an accretive M&A (merger and acquisition) transaction. Under her watch, Biofrontera completed a successful initial public offering (IPO) listing on the Nasdaq Stock Market in 2021 and follow on equity investment rounds in excess of $60-million.

Ms. Monaco holds a master of accounting degree from the Isenberg School of Management at the University of Massachusetts, Amherst, and holds an active CPA licence.

"We are delighted to welcome Erica to our leadership team" stated Dr. Raza Bokhari, executive chairman and chief executive officer. "Erica brings immense business leadership experience in non-melanoma skin diseases (NMSD), strengthening our efforts to deliver a first in class, novel, non-invasive alternative to treat basal cell carcinoma (BCC) of the skin, using dissolvable microneedle arrays loaded with the chemotherapeutic agent doxorubicin (D-MNA)."

The company also announced that it is has engaged a full-service investment bank in the United States to advise on potential financings and U.S. listing opportunities. Information on any future financings will be released once available in accordance with applicable securities laws.

The company also announced that it has engaged Renmark Financial Communications Inc. to increase market and brand awareness of the company and to broaden its reach within the investment community.

Under the agreement, Renmark will receive compensation of $8,000 per month, payable monthly in advance. The agreement is for an initial term of seven months commencing on March 1, 2024, and ending on Sept. 30, 2024, and will renew for additional one-month terms unless terminated.

Renmark Financial Communications does not have any interest, directly or indirectly, in Medicus Pharma or its securities, or any right or intent to acquire such an interest.

About Medicus Pharma Ltd.

Medicus Pharma is a holding company focused on accelerating clinical development programs of novel life sciences and bio-technology companies.

We seek Safe Harbor.